0000000001001449

AUTHOR

L. Ferrari

showing 9 related works from this author

Zygomycosis in Italy: A survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology)

2009

Abstract The aims of the study were to analyze the clinical and epidemiological characteristics and treatments for patients who developed zygomycosis enrolled in Italy during the European Confederation of Medical Mycology of medical mycology survey. This prospective multicenter study was performed between 2004 and 2007 at 49 italian Departments. 60 cases of zygomycosis were enrolled: the median age was 59.5 years (range 1-87), with a prevalence of males (70%). The majority of cases were immunocompromised patients (42 cases, 70%), mainly hematological malignancies (37). Among non-immunocompromised (18 cases, 30%), the main category was represented by patients with penetrating trauma (7/18, 3…

AdultMalemedicine.medical_specialtyAdolescentEpidemiologyAntifungal drugImmunocompromised HostPharmacotherapyZygomycosisDrug Resistance FungalAmphotericin BInternal medicineEpidemiologymedicineHumansPharmacology (medical)ChildMycosisAgedPharmacologyImmunocompromised hostAged 80 and overbusiness.industryMortality rateMucormycosisInfantEpidemiology; Immunocompromised host; ZygomycosisMiddle Agedmedicine.diseaseSurgeryInfectious DiseasesOncologyItalyChild PreschoolFemaleZygomycosisbusinessmedicine.drug
researchProduct

Study of Microcalorimeters for Astrophysics Applications

2008

In the framework of the Italian Space Agency R&D project, which is focused on the development of microcalorimeters for applications on astrophysics, we are studying different methods for TES microcalorimeter production and developing simulations of various absorber performances. In this paper are presented preliminary results obtained with two different geometries: front back and planar on SiN membrane.

PhysicsGeneral Materials ScienceAstrophysicsCondensed Matter PhysicsAtomic and Molecular Physics and OpticsX-ray detectors microcalorimeters TES
researchProduct

Development of a TES based Cryo-Anticoincidence for a large array of microcalorimeters

2009

The employment of large arrays of microcalorimeters in space missions (IXO, EDGE/XENIA)[1][2][3], requires the presence of an anticoincidence detector to remove the background due to the particles, with a rejection efficiency at least equal to Suzaku (98%) [1]. A new concept of anticoincidence is under development to match the very tight thermal requirements and to simplify the design of the electronic chain. The idea is to produce a Cryo-AntiCoincidence (Cryo-AC) based on a silicon absorber and read by a TES (Transition-Edge Sensor). This configuration would ensure very good performances in terms of efficiency, time response and signal to noise ratio. We present the results of estimations,…

Physicsbusiness.industryLarge arrayBolometerDetectorParticle detectorSpace explorationlaw.inventionPhysics and Astronomy (all)OpticsSignal-to-noise ratioMicrocalorimeterlawThermalDevelopment (differential geometry)Particle detectorX-ray detectors microcalorimeters backgroundAnticoincidencebusinessAnticoincidence; Microcalorimeter; Particle detector; TES; X ray detector; Physics and Astronomy (all)TESX ray detectorAIP Conference Proceedings
researchProduct

TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC)

2012

ABSTRACT Background TH-302 is a hypoxia targeted prodrug with a hypoxia-triggered 2-nitroimidazole component designed to release the DNA alkylator, bromo-isophosphoramide mustard (Br-IPM), when reduced in severe hypoxia. A randomized Phase 2B study (NCT01144455) was conducted to assess the benefit of G + T to standard dose G as first-line therapy of PAC. Materials and methods An open-label multi-center study of two dose levels of TH-302 (240 mg/m2 or 340 mg/m2) in combination with G versus G alone (randomized 1:1:1). G (1000 mg/m2) and T were administered IV over 30-60 minutes on Days 1, 8 and 15 of a 28-day cycle. Patients on the G could crossover after progression and be randomized to a G…

medicine.medical_specialtyGastrointestinal tumorsPerformance statusbusiness.industryHematologySevere hypoxiaNeutropeniamedicine.diseaseRashGastroenterologyDiscontinuationNon colorectalOncologyInternal medicineToxicitymedicinemedicine.symptombusinessAnnals of Oncology
researchProduct

The TES-based cryogenic anticoincidence detector for IXO: First results from large area prototypes

2010

The technique which combines high resolution spectroscopy with imaging capability is a powerful tool to extract fundamental information in X-ray Astrophysics and Cosmology. TES (Transition Edge Sensors)-based microcalorimeters match at best the requirements for doing fine spectroscopy and imaging of both bright (high count rate) and faint (poor signal-to-noise ratio) sources. For this reason they are considered among the most promising detectors for the next high energy space missions and are being developed for use on the focal plane of the IXO (International X-ray Observatory) mission. In order to achieve the required signal-to-noise ratio for faint or diffuse sources it is necessary to r…

Cryogenic Detectors; IXO; SQUID; TES; X-ray; Electronic Optical and Magnetic Materials; Condensed Matter Physics; Computer Science Applications1707 Computer Vision and Pattern Recognition; Applied Mathematics; Electrical and Electronic EngineeringCryogenic DetectorsSQUIDSpace explorationX-raySignal-to-noise ratioOpticsSettore FIS/05 - Astronomia E AstrofisicaObservatoryElectronicOptical and Magnetic MaterialsElectrical and Electronic EngineeringPhysicsSpectrometerPixelbusiness.industryApplied MathematicsDetectorPulse durationComputer Science Applications1707 Computer Vision and Pattern RecognitionCondensed Matter PhysicsCardinal pointIXObusinessTES Cryogenic Detectors X-ray SQUID IXOTES
researchProduct

TES microcalorimeter for IXO: From focal plane to anticoincidence detector

2009

The high resolution spectroscopy provides a unique technique to extract fundamental information in X-ray Astrophysics and Cosmology. In order to exploit at the best the capability of carrying out spectroscopy of faint sources, great care must be taken to reduce the background in the main detector. In this paper, we will present the working principle of a TES (Transition Edge Sensor) Microcalorimeter, its application for fine spectroscopy and a novel anticoincidence technique , based itself on a TES detector. Recent results from the first sample of the IXO-anticoincidence detector will be also shown.

Settore FIS/05 - Astronomia E AstrofisicaMultidisciplinary
researchProduct

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast ca…

2017

Abstract Background The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant. Patients and methods This study aimed to describe the outcome of ABC pts treated with EVE-EXE combination in terms of median duration of EVE treatment and ORR in a real-life setting. Resul…

0301 basic medicineOncologyReceptor ErbB-2chemistry.chemical_compoundErbB-20302 clinical medicineDose-intensityExemestane80 and overNeoplasm MetastasisFulvestrantAged 80 and overeducation.field_of_studyAdvanced breast cancer Dose-intensity Everolimus Fulvestrant Hormone-receptor positiveAdvanced breast cancer; Dose-intensity; Everolimus; Fulvestrant; Hormone-receptor positive; Adult; Aged; Aged 80 and over; Androstadienes; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor ErbB-2; SurgeryGeneral MedicineMiddle AgedEverolimu030220 oncology & carcinogenesisAdvanced breast cancerFemaleAdvanced breast cancer; Dose-intensity; Everolimus; Fulvestrant; Hormone-receptor positive; SurgeryReceptormedicine.drugAdultmedicine.medical_specialtyPopulationSocio-culturaleBreast NeoplasmsHormone-receptor positive03 medical and health sciencesBreast cancerAdvanced breast cancer; Dose-intensity; Everolimus; Fulvestrant; Hormone-receptor positive; Adult; Aged; Aged 80 and over; Androstadienes; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor ErbB-2Internal medicinemedicineHumansEverolimusAdverse effecteducationAgedNeoplasm StagingGynecologyEverolimusFulvestrantbusiness.industryfungiCancermedicine.diseaseAndrostadienesClinical trial030104 developmental biologychemistrySurgerybusinessFollow-Up StudiesThe Breast
researchProduct

Italian cancer figures, report 2014: Prevalence and cure of cancer in Italy

2015

This Report intends to estimate the total number of people still alive in 2010 after cancer diagnosis in Italy, regardless of the time since diagnosis, and to project these estimates to 2015. This study is also aimed to estimate the number of already cured cancer patients, whose mortality rates have become undistinguishable from that of the general population of the same age and sex.The study took advantage of the information from the AIRTUM database, which included 29 Cancer Registries (covering 21 million people, 35% of the Italian population). A total of 1,624,533 cancer cases diagnosed between 1976 and 2009 contributed to the study. For each registry, the observed prevalence was calcula…

Aged 80 and overMaleMedicine (all)Aged; Aged 80 and over; Female; Humans; Italy; Male; Middle Aged; Neoplasms; Prevalence; Registries; Survival RateSocio-culturaleMiddle AgedSettore MED/42 - Igiene Generale E ApplicataSurvival RateItalyNeoplasms80 and overPrevalenceHumanscancer prevalence cancer incidence cancer in ItalyFemaleRegistriesAged
researchProduct

ORIGIN: metal creation and evolution from the cosmic dawn

2012

Herder, Jan-Willem den et al.

HOT INTERGALACTIC MEDIUMUNIVERSEChemical evolutionMission7. Clean energy01 natural sciencesSpectral lineSettore FIS/05 - Astronomia E Astrofisica010303 astronomy & astrophysicsmedia_commonPhysicsHigh Energy Astrophysical Phenomena (astro-ph.HE)NUCLEOSYNTHESISCOSMIC cancer databaseClusters of galaxiesSatellite MissionEpoch (reference date)Astrophysics::Instrumentation and Methods for AstrophysicsFORESTGALAXIESGamma-ray burstsAstrophysics - Instrumentation and Methods for AstrophysicsAstrophysics - High Energy Astrophysical PhenomenaX-ray Mission Gamma-ray bursts Clusters of galaxies Warm-hot intergalactic medium Chemical evolutionWarm-hot intergalactic mediumAstrophysics - Cosmology and Nongalactic AstrophysicsAstrophysics and AstronomyStructure formationCosmology and Nongalactic Astrophysics (astro-ph.CO)Clusters of galaxiemedia_common.quotation_subjectAstrophysics::High Energy Astrophysical PhenomenaREDSHIFTFOS: Physical sciencesAstrophysics::Cosmology and Extragalactic AstrophysicsX-ray Mission Gamma-ray bursts Clusters of galaxies Warm-hot intergalactic medium Chemical evolutionABSORPTION-SPECTRA010309 opticsX-rayYIELDS0103 physical sciencesGamma-ray burstInstrumentation and Methods for Astrophysics (astro-ph.IM)X-ray; Mission; Gamma-ray bursts; Clusters of galaxies; Warm-hot intergalactic medium; Chemical evolutionAstronomyAstronomy and AstrophysicsRedshiftGalaxyUniverse13. Climate actionChemical evolution; Clusters of galaxies; Gamma-ray bursts; Mission; Warm-hot intergalactic medium; X-ray; Astronomy and Astrophysics; Space and Planetary ScienceSpace and Planetary ScienceGamma-ray burstCLUSTERSExperimental Astronomy
researchProduct